Cargando…

Skin-impedance in Fabry Disease: A prospective, controlled, non-randomized clinical study

BACKGROUND: We previously demonstrated improved sweating after enzyme replacement therapy (ERT) in Fabry disease using the thermo-regularity sweat and quantitative sudomotor axon reflex tests. Skin-impedance, a measure skin-moisture (sweating), has been used in the clinical evaluation of burns and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Surya N, Ries, Markus, Murray, Gary J, Quirk, Jane M, Brady, Roscoe O, Lidicker, Jeffrey R, Schiffmann, Raphael, Moore, David F
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585087/ https://www.ncbi.nlm.nih.gov/pubmed/18990229 http://dx.doi.org/10.1186/1471-2377-8-41

Ejemplares similares

The Saccadic and Neurological Deficits in Type 3 Gaucher Disease
por: Benko, William, et al.
Publicado: (2011)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Arterial Wall Properties and Womersley Flow in Fabry Disease
por: Moore, David F, et al.
Publicado: (2002)

The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease
por: Schiffmann, Raphael, et al.
Publicado: (2019)

Vitamin C Urinary Loss in Fabry Disease: Clinical and Genomic Factors of Vitamin C Renal Leak
por: Ebenuwa, Ifechukwude, et al.
Publicado: (2022)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Dysregulated DNA methylation in the pathogenesis of Fabry disease
por: Shen, Jin-Song, et al.
Publicado: (2022)

Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey
por: Morand, Olivier, et al.
Publicado: (2019)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Comparison of efficacy between subcutaneous and intravenous application of moss‐aGal in the mouse model of Fabry disease
por: Dabrowska‐Schlepp, Paulina, et al.
Publicado: (2023)

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
por: Schiffmann, Raphael, et al.
Publicado: (2014)

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
por: Schiffmann, Raphael, et al.
Publicado: (2009)

A Scientist’s Warning to humanity on human population growth
por: Lidicker, William Z.
Publicado: (2020)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
por: Wu, Xiaoyang, et al.
Publicado: (2011)

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
por: Benjamin, Elfrida R., et al.
Publicado: (2017)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Impedance spectroscopy of changes in skin-electrode impedance induced by motion
por: Cömert, Alper, et al.
Publicado: (2014)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
por: Shen, Jin-Song, et al.
Publicado: (2015)

Access Impediments to Health Care and Social Services Between Anglophone and Francophone African Immigrants Living in Philadelphia with Respect to HIV/AIDS
por: Simbiri, Kenneth Omollo A., et al.
Publicado: (2009)

Dependence of Skin-Electrode Contact Impedance on Material and Skin Hydration
por: Goyal, Krittika, et al.
Publicado: (2022)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
por: Fall, Brent, et al.
Publicado: (2016)

Prospective study comparing skin impedance with EEG parameters during the induction of anaesthesia with fentanyl and etomidate
por: Winterhalter, M, et al.
Publicado: (2010)

Longitudinal Impedance of Skinned Frog Muscle Fibers
por: Mobley, Bert A., et al.
Publicado: (1974)

Ulcerated skin evaluation by electrical impedance measurements
por: Kawałkiewicz, Weronika, et al.
Publicado: (2023)

COVID-19 in Fabry disease: a reference center prospective study
por: Bothou, Christina, et al.
Publicado: (2022)

Circulating microRNAs in Fabry Disease
por: Xiao, Ke, et al.
Publicado: (2019)

Fabry Cardiomyopathy: Current Practice and Future Directions
por: Yim, Jeffrey, et al.
Publicado: (2021)

Fabry-Perot interferometers
por: Mora-Hernandez, G
Publicado: (1988)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

Time Evolution of the Skin–Electrode Interface Impedance under Different Skin Treatments
por: Murphy, Brendan B., et al.
Publicado: (2021)

Parsing Fabry Disease Metabolic Plasticity Using Metabolomics
por: Ducatez, Franklin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1m3jcqeif0e92tpuddue0lpl0s